Sustainability & Climate

Backed by $18M in seed funding, 25-year-old founder Harry Gestetner is launching an AI-powered smart mattress cover to transform longevity through sleep.

A new alliance between Guardant Health and Trial Library uses AI and massive datasets to dismantle barriers, connecting more patients to vital cancer research.

Engineering giant Amentum will leverage advanced tech in a decade-long, multi-billion dollar effort to help nations combat nuclear and biological threats.

KB Home's sixth consecutive corporate responsibility award offers a surprising blueprint for the healthcare sector. Can a homebuilder's ESG strategy pay off for pharma?

As quantum threats loom, SEALSQ's strategic entry into medical chips with post-quantum cryptography could redefine data security and the industry's supply chain.

CardCash's record November reveals a major shift in consumer behavior, where shoppers are using discounted gift cards as a tool to fight inflation.

Xtant Medical's new nanOss Strata bone graft isn't just an update; it's a strategic move to disrupt the orthobiologics market. Here's why it matters.

Polyrizon's novel hydrogel shows it can stick to nasal tissue longer without slowing drug delivery, a key innovation in the fight against opioid overdose.

New Phase 2 data shows Elicio's off-the-shelf therapy ELI-002 7P induces "antigen spreading," creating a personalized anti-tumor response.

Beyond a simple acquisition, ZenaTech is executing a bold strategy to digitize the American West, transforming old-guard industries with a DaaS network.

Cadrenal Therapeutics acquires a novel Phase 2 drug for a deadly clotting disorder, a strategic move targeting an underserved $1 billion market.

Praxis Precision Medicines secures a clear path to market for its rare epilepsy drug, blending genetic science with a savvy regulatory strategy.

Ghost Robotics' new arm gives its Vision 60 the power to act. This leap from seeing to doing has huge implications for industries from defense to healthcare.

Brii Biosciences partners with OpenBench, using an AI platform where they only pay for results. Is this the future of de-risking pharmaceutical R&D?

After a decade of failed trials, a new drug shows promise in treating resistant lung cancer by reawakening the immune system and halting its spread.

As elder isolation becomes a public health emergency in Quebec, one non-profit's strategy of sustained human connection offers a powerful brand lesson.

With AI-guided drills and a new discovery, Nevada King aims to transform its Atlanta mine into a major US gold asset. Will the market take notice?

Rezolute's stock plummets after its lead drug fails a key trial, raising questions about its future and highlighting the brutal realities of biotech.

Dreame's 2025 holiday sale isn't just about vacuums; it's a strategic play to conquer the UK market with premium tech at aggressive prices.

With its pivotal trial fully enrolled, IDEAYA Biosciences is on track for a 2026 FDA filing for a new treatment in a rare, deadly eye cancer.